KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
68 hedge funds and large institutions have $398M invested in KalVista Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 6 closing their positions.
183% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 6
52% more capital invested
Capital invested by funds: $261M → $398M (+$137M)
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
19% more funds holding
Funds holding: 57 → 68 (+11)
3.33% more ownership
Funds ownership: 77.28% → 80.61% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$23.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.9M |
| 3 |
Millennium Management
New York
|
+$2.09M |
| 4 |
O
OrbiMed
New York
|
+$1.96M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SHI
SV Health Investors
Boston,
Massachusetts
|
-$15.5M |
| 2 |
VMI
VHCP Management III
New York
|
-$6.81M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$4.99M |
| 4 |
VMI
VHCP Management II
New York
|
-$4.03M |
| 5 |
BC
Broadfin Capital
New York
|
-$2.83M |
KALV Hedge Fund Activity: Q1 2019 in Review
68 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2019, worth a combined $398M — up 52% from $261M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KALV positions and 6 closed out — a net gain of 11 holders — while 20 added to existing stakes and 16 trimmed.
The largest buyer was Polar Capital, adding an estimated $23.2M. The largest seller was SV Health Investors, cutting an estimated $15.5M.
- 68 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2019, up from 57 in Q4 2018.
- Funds reported $398M of KalVista Pharmaceuticals stock for Q1 2019, up 52% quarter-over-quarter.
- 17 funds opened new KalVista Pharmaceuticals positions in Q1 2019 and 6 closed out, a net change of +11 holders.
- The largest KalVista Pharmaceuticals buyer in Q1 2019 was Polar Capital, an estimated $23.2M added.
- The largest KalVista Pharmaceuticals seller in Q1 2019 was SV Health Investors, an estimated $15.5M sold.
Based on aggregated 13F filings for Q1 2019.